OKYO Pharma CEO to Present at GPCR Drug Discovery Summit
Ticker: OKYO · Form: 6-K · Filed: May 19, 2025 · CIK: 1849296
Sentiment: neutral
Topics: presentation, drug-discovery, biotech
TL;DR
OKYO Pharma CEO speaking May 22nd on drug development at GPCR summit.
AI Summary
On May 19, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. The presentation will focus on the development of urc.
Why It Matters
This presentation provides an opportunity for OKYO Pharma to showcase its drug development progress in the GPCR space to industry experts and potential investors.
Risk Assessment
Risk Level: low — This filing is an announcement of a presentation and does not contain material financial or operational changes.
Key Players & Entities
- OKYO Pharma LTD (company) — Registrant
- Gary S. Jacob, Ph.D. (person) — CEO of OKYO Pharma LTD
- May 19, 2025 (date) — Filing Date
- May 22, 2025 (date) — Presentation Date
- 4th Annual GPCRs-Targeted Drug Discovery Summit (event) — Summit where CEO will present
- Boston, MA (location) — Location of Summit
FAQ
What is the specific topic of CEO Gary S. Jacob's presentation?
The filing states that Dr. Jacob's presentation will cover the development of urc.
When and where will the presentation take place?
The presentation will take place on May 22, 2025, in Boston, MA, at the 4th Annual GPCRs-Targeted Drug Discovery Summit.
What is the exact name of the company filing this report?
The exact name of the company is OKYO Pharma LTD.
What form is this SEC filing?
This is a Form 6-K report.
What is the filing date of this report?
The filing date is May 19, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 19, 2025 by Gary S. Jacob, Ph.D. regarding OKYO Pharma Ltd (OKYO).